Cutaneous scarring: Pathophysiology, molecular mechanisms, and scar reduction therapeutics : Part I. The molecular basis of scar formation - 16/12/11
Doi : 10.1016/j.jaad.2011.05.055
Christos Profyris, MA, BM, BCh (Oxon), MRCS (Eng) a, Christos Tziotzios, MA, MB, BChir (Cantab), MRCP (UK) b, ⁎ 
, Isabel Do Vale, MB, BCh (Wits) c
, Isabel Do Vale, MB, BCh (Wits) c a Department of Plastic and Burns, Chelsea and Westminster Hospital, London, United Kingdom
b Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
c Department of Plastic and Reconstructive Surgery, Charlotte Maxeke Johannesburg Academic Hospital, Parktown, South Africa
Reprint requests: Christos Tziotzios, MA, MB, BChir (Cantab), MRCP (UK), Addenbrooke’s Hospital, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge CB2 0QQ, Cambridge, United Kingdom.Abstract |
Cutaneous scarring is often the epicenter of patient-related concerns, and the question “Will there be a scar?” is one that is all too familiar to the everyday clinician. In approaching this topic, we have reviewed the pathology, the embryology, and the molecular biology of cutaneous scarring.
Le texte complet de cet article est disponible en PDF.Key words : cutaneous scar, early growth response protein-1, homeobox13, interleukins, mechanisms of scarring, platelet-derived growth factor, transforming growth factor–beta, Wnt pathway
Abbreviations used : EGR-1, IL, PDGF, TGFβ
Plan
© 2011
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 66 - N° 1
P. 1-10 - janvier 2012 Retour au numéro
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?